Citi Assumes PTC Therapeutics (PTCT), Upgrades to Buy
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $82.13 +1.45%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Citi analyst Eric Joseph assumed coverage and upgraded PTC Therapeutics (NASDAQ: PTCT) from Neutral to Buy with a price target of $108.00 (from $75.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $70.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Lockheed Martin wins $8.4B missile contract modification
- U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT
Create E-mail Alert Related Categories
Hot Upgrades, New Coverage, UpgradesRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
